IDH1 and central nervous system cancer: As such, IDH mutations may be predictive markers for genotoxic therapies in grade II and grade III gliomas as a whole, while 1p/19q codeletion status may only be predictive in certain histology types such as oligodendroglial and oligoastrocytic gliomas.